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Abstract
Background: Medical treatment with misoprostol is a non-invasive and inexpensive treatment option in first
trimester miscarriage. However, about 30% of women treated with misoprostol have incomplete evacuation of the
uterus. Despite being relatively asymptomatic in most cases, this finding often leads to additional surgical treatment
(curettage). A comparison of effectiveness and cost-effectiveness of surgical management versus expectant
management is lacking in women with incomplete miscarriage after misoprostol.
Methods/Design: The proposed study is a multicentre randomized controlled trial that assesses the costs and
effects of curettage versus expectant management in women with incomplete evacuation of the uterus after
misoprostol treatment for first trimester miscarriage.
Eligible women will be randomized, after informed consent, within 24 hours after identification of incomplete
evacuation of the uterus by ultrasound scanning. Women are randomly allocated to surgical or expectant
management. Curettage is performed within three days after randomization.
Primary outcome is the sonographic finding of an empty uterus (maximal diameter of any contents of the uterine
cavity < 10 millimeters) six weeks after study entry. Secondary outcomes are patients’ quality of life, surgical
outcome parameters, the type and number of re-interventions during the first three months and pregnancy rates
and outcome 12 months after study entry.
Discussion: This trial will provide evidence for the (cost) effectiveness of surgical versus expectant management in
women with incomplete evacuation of the uterus after misoprostol treatment for first trimester miscarriage.
Trial registration: Dutch Trial Register: NTR3110
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Background
Miscarriage is a frequent complication in first trimes-
ter pregnancy which occurs in 10-15% of pregnant
women and results in between 18.000 and 27.000
miscarriages in The Netherlands each year [1]. In the
past, Dutch women diagnosed with miscarriage were
either managed expectantly, with complete expulsion
of the products of conception knowing to occur
within two weeks in 50% of women, or were offered
surgical management (curettage) as an alternative
option [2,3]. Only recently, medical treatment with
misoprostol has been introduced as an outpatient and
inexpensive treatment option, which is available on
demand and easy to use. Treatment with misoprostol
is effective in 50-80% of women with miscarriages
[4-11]. Initial treatment with misoprostol seems to be
more cost-effective than immediate curettage, especially
in specific subgroups of women [12-15]. There are no
significant differences between the use of misoprostol
versus curettage on pelvic infections or ongoing preg-
nancies during follow-up [16].
According to a national survey in 2010, about 50% of
Dutch hospitals use misoprostol in the management of
miscarriage, and this figure probably underestimates its
current use [17]. Misoprostol is currently applied in
about 10,000 women with miscarriages each year in The
Netherlands.
A problem in the treatment with misoprostol is that
approximately one third of women show incomplete
evacuation on ultrasound scanning during follow-up,
despite being relatively asymptomatic [18,19]. Although
misoprostol is used ever more frequently, the sonographic
image of incomplete evacuation still leads to additional
surgery, i.e. curettage.
We estimate that surgical management is applied in
approximately 3,000 of these women who, despite having
experienced a clinically successful miscarriage after
misoprostol administration, are left with incomplete
evacuation as diagnosed sonographically. If expectant
management would turn out to be (cost)effective as
compared to curettage, this could potentially save
3.000 surgical procedures -i.e. curettages.
There is no doubt that curettage is an effective
treatment for women with an incomplete miscarriage,
but it also includes the risk on perforation and the
forming of intra-uterine adhesions, in particular in
women with a previous curettage. It is unknown
whether curettage is also cost effective in relatively
asymptomatic women with sonographic evidence of
incomplete evacuation after initial misoprostol treatment
for miscarriage.
A comparison of surgical management versus expect-
ant management is still lacking and data on the costs of
both strategies are not available.
Methods/Design
Objective
The objective of this study is to compare the (cost)
effectiveness of surgical versus expectant management in
women with sonographic evidence for incomplete evacu-
ation of the uterus after misoprostol treatment for first
trimester miscarriage.
Participants/eligibility criteria
All women > 18 years with sonographic evidence of
incomplete evacuation of the uterus, one to two weeks
after having been treated initially with misoprostol for a
first trimester miscarriage, are informed on the trial.
They can participate in the trial when they have an
intra-uterine remnant or an anterio-posterior diameter
of the uterine cavity of ≥ 10 millimeters. Exclusion
criteria are severe vaginal bleeding or severe abdominal
pain that needs acute intervention, fever (> 38.0 Celcius) or
sepsis requiring antibiotic treatment and curettage, contra-
indications for curettage, or a failed misoprostol-induced
miscarriage with an intact gestational sac still in utero.
Procedures, recruitment, randomization, collection of
baseline data
The study is a multicentre randomized controlled study.
The study is performed within the Dutch Consortium
for Studies in Women’s Health and Reproductivity
(www.studies-obsgyn.nl). Participating hospitals can be
district, teaching or third referral hospitals. 25 Hospitals are
participating at this moment, and we expect participation
of at least five more hospitals.
Before study entry, women are informed about the
aims, methods, reasonably anticipated benefits and po-
tential hazards of the study. They are informed that their
participation is voluntary and that they may withdraw
consent to participate at any time during the study.
Choosing not to participate will not affect care. An
independent gynecologist is available. Women are asked
to decide whether or not to participate in this study within
24 hours after counselling. Written informed consent
is obtained. The consent form must be signed before
performance of any study-related activity. Eligible patients
are randomly allocated to either curettage within 3
workdays (experimental strategy) or expectant manage-
ment (control strategy). Randomisation is performed
through a web-based database located in the central
data collection unit in the Academic Medical Centre in
Amsterdam. Patients who refuse to participate in the
trial are asked to take part in the observational arm of
the study. Due to the nature of the two treatment options
blinding will not be possible.
Baseline demographic, obstetric and medical histories are
recorded for all women, including number of previous mis-
carriages and curettages. Gestational age and transvaginal
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findings at misoprostol use in the index pregnancy and
endometrial thickness at randomization are registered.
All details of treatment and follow-up are recorded in
a case record form that is accessible for authorised
research personnel through a website http://www.studies-
obsgyn.nl/misorest.
Interventions and follow up
Women allocated to surgical management are scheduled
for curettage under general, regional or local anesthesia
in a day-care setting within three days after randomization.
Transvaginal sonographic examination is scheduled six
weeks after curettage (Figure 1).
Women allocated to expectant management receive
no further treatment. There is a consultation by telephone
two weeks after randomization by a research nurse.
Transvaginal sonographic examination is scheduled six
weeks after randomization. In case of severe complaints,
defined as heavy vaginal bleeding or severe abdominal pain,
or the occurrence of fever (> 38.0 Celcius) an emergency
curettage will be performed.
In both groups, in case of persisting abnormalities at
sonographic examination six weeks after randomization,
women will be scheduled for (re-)curettage.
Outcome measures
The main outcome measure is the sonographic finding
of an empty uterus (maximal diameter of any contents
of the uterine cavity < 10 millimeters) six weeks after
study entry/randomization.
Secondary outcomes are patients’ quality of life,
measured with validated questionnaires at baseline
(before randomization), 1–2 weeks, 4 weeks and 3 months
after randomization; surgical outcome parameters; the
type and number of any re-interventions during the first
three months; pregnancy rates 12 months after study
entry, with the recording of unexposed cycles and cycles
in which contraceptives were used; and costs.
Questionnaires used for Quality of Life measurement
are the Hospital Anxiety and Depression Scale (HADS),
the Short Form Health Survey (SF-36), Recovery Index
(RI-10) and EuroQol Health Questionnaire (EQ-5D). At
baseline HADS, RI-10, EQ-5D will be registered four
weeks after study entry, HADS, SF-36 and RI-10 will be
completed. 12 months after study entry patients will be
asked to fill in a questionnaire about their desire for
future pregnancy and the occurrence and outcome of a
next pregnancy. In case the patient does not return the
questionnaires, a reminder is sent.
Figure 1 Flowchart. MisoREST trial: randomisation and follow-up.
Verschoor et al. BMC Pregnancy and Childbirth 2013, 13:102 Page 3 of 5
http://www.biomedcentral.com/1471-2393/13/102
Economic evaluation
The economic evaluation will be performed alongside the
clinical trial and from a societal perspective. It is designed
as a cost-effectiveness analysis of surgical management as
compared to expectant management, estimating the costs
per patient with a complete evacuation of the uterus as
primary outcome. All relevant costs will be measured,
such as direct medical costs (health care consumption),
direct non-medical costs (informal care) and indirect costs
(costs of production loss).
Volumes of health care resource use are measured
prospectively using the case record form. Health resource
use outside the hospital is recorded by questionnaires
filled out by the patients 3 months after randomization.
The Health and Labor Questionnaire is used to document
absence from paid work [20].
This evaluation will provide insight on whether expect-
ant management in women with incomplete evacuation of
the uterus after misoprostol treatment for miscarriage will
reduce costs as compared to surgical management.
Statistical issues
Sample size
The primary study question is phrased as a superiority
hypothesis of surgical management versus expectant
management. Surgical management is expected to lead
to a higher proportion of patients successfully treated,
but we anticipate that women will prefer expectant man-
agement if the proportion of success for curettage is not
substantially higher. Anticipating a 98% success rate with
curettage, versus 85% for expectant management, we
would need to randomise 130 patients on a 1:1 basis.
Assuming a drop-out rate of 20%, we plan to include
162 patients in total (81 per arm).
A one-sided 95.0% confidence interval for a ln
(relative risk) expected to be 0.142 will extend 0.091 from
the observed ln(relative risk) (corresponding to confidence
limits of 1.053 and/or 1.262 for a relative risk of 1.153).
Data analysis
Data will be analyzed according to the intention to treat
principle. Within each group, we will calculate the pro-
portion of randomized women with an empty uterus,
as verified by ultrasound scanning. The effectiveness of
surgical management versus expectant management is
expressed as a relative risk, with 95% confidence interval.
Univariate and multivariate logistic regression analyses
are used to analyse the relative contribution of findings
on ultrasound versus other predictive factors for complete
evacuation on misoprostol treatment, like age, parity and
gestational age at initial treatment.
A linear mixed model is used for comparison of the
study groups on SF-36 and HADS summary scores while
accounting for the baseline values.
Differences in pregnancy rates 12 months after study
entry in both study groups will be compared using
Kaplan Meier curves and tested with the log-rank test,
thereby censoring for unexposed cycles and for cycles
where contraceptives were used.
The economic analysis will be done according to the
intention-to-treat principle. Missing data will be imputed
using multiple imputation techniques. We will compare
the differences in total costs between the two interventions
to difference in effect, expressed as the costs per completely
cured patient (complete evacuation of the uterus six weeks
after randomization). We will also perform a cost-utility
analysis based on the EQ-5D. Bootstrapping will be used
for pair-wise comparison of the mean differences in total
costs. Cost-effectiveness and cost-utility ratios will be
estimated using bootstrapping techniques and graphically
presented on cost-effectiveness planes and cost-effectiveness
acceptability curves.
Data safety monitoring committee
Serious Adverse Events (SAE’s) will be reported to a
Data Safety Monitoring Committee (DSMC). The DSMC
can order to perform an interim analysis and, if indicated,
terminate the trial prematurely.
Interim analysis
Because of the relatively small sample size and the
expected duration of inclusion no interim analysis will
be performed. This was approved by the DSMC. The
study group has already completed studies comparing
curettage versus expectant management and studies
comparing misoprostol versus curettage in women with
a first trimester miscarriage. No serious adverse events
have been recorded within these studies.
Ethical consideration
This study is approved by the National Central Committee
on Research involving Human Subjects (CCMO - NL38637.
018.11), by the ethics committee of the Academic Medical
Centre Amsterdam (Ref. No. 11–373) and by the boards of
management of all participating hospitals.The trial is
registered in the Dutch Trial Register (NTR3110, http://
www.trialregister.nl).
Discussion
Recently, medical treatment with misoprostol was in-
troduced as a non-invasive and cost effective treat-
ment option in women with first trimester miscarriage.
However, approximately 30% of women show incom-
plete evacuation of the uterus on ultrasound scan-
ning during follow-up. This still leads to additional
surgery in a substantial part of women receiving miso-
prostol, i.e. curettage, although most women are rela-
tively asymptomatic.
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This study is designed to compare the (cost) effectiveness
of surgical management versus expectant management in
women with sonographic evidence of incomplete evacu-
ation of a miscarriage after primary misoprostol treatment.
To our knowledge there are no other ongoing trials in the
Netherlands or other countries evaluating this subject. It is
anticipated that the outcome of this study can save up to
3000 surgical procedures in The Netherlands yearly.
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